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Abstract
Background: The Hangzhou criteria expand the Milan criteria safely and effectively in selecting hepatocellular
carcinoma (HCC) candidates for liver transplantation (LT), but some patients exceeding the Milan but fulfilling the
Hangzhou criteria still show poor outcomes due to early tumor recurrence. In this study, the platelet-to-lymphocyte
ratio (PLR) was employed to differentiate high-risk tumor recurrence recipients, and a new method combining PLR
and the Hangzhou criteria was established.
Methods: The clinical data of 343 LT for HCC were retrospectively analyzed. Receiver operating characteristic (ROC)
analysis was used to determine the PLR cut-off value to stratify patients exceeding the Milan but fulfilling the
Hangzhou criteria. The recurrence-free survival (RFS) of recipients was compared after stratification. The Hangzhou
criteria & PLR method was proposed and its feasibility was validated by ROC analysis.
Results: PLR 120 was the most significant cut-off value when comparing RFS of patients exceeding the Milan but
fulfilling the Hangzhou criteria. After stratification, the 1-, 3-, and 5-year RFS of patients exceeding the Milan but
fulfilling the Hangzhou criteria with PLR < 120 were 84.2%, 73.3%, and 73.3%, respectively, comparable with 85.7%,
73.9%, and 72.8%, respectively, in patients fulfilling the Milan criteria (P = 0.885). Patients exceeding the Milan but
fulfilling the Hangzhou criteria with PLR ≥ 120 showed poor outcomes, which were similar in patients exceeding
the Hangzhou criteria; 1-, 3-, and 5-year RFS were only 37.5%, 12.5%, and 12.5% vs. 32.3%, 17.6%, and 15.1%,
respectively (P = 0.887). ROC analysis demonstrated that the ROC area of the Hangzhou criteria & PLR method was
0.768 for RFS. Multivariate analysis confirmed that PLR ≥ 120 was independently associated with RFS of patients
exceeding the Milan but fulfilling the Hangzhou criteria.
Conclusions: The Hangzhou criteria combined with the pre-transplant PLR can accurately exclude high-risk tumor
recurrence recipients; this approach expands the Milan criteria effectively without any sacrifice.
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Background
Hepatocellular carcinoma (HCC) ranks fifth in morbidity,
and third in mortality of cancer in the world [1]. In 2012,
the estimated number of new liver malignancy and deaths
were 782,500 and 745,500, respectively. Unfortunately,
about half of the new cases and deaths of liver cancer hap-
pened in China [2]. Liver transplantation (LT) provides
the best prognosis for well-selected HCC patients by
removing both the tumor and the underlying carcinogenic
liver. In the early period, the outcome of LT for HCC was
disappointing because of the high tumor recurrence rate
of about 30–40% [3, 4]. This situation has changed dra-
matically since the introduction of the Milan criteria (a
solitary HCC nodule 5.0 cm or less in diameter or no
more than 3 tumor nodules and each 3.0 cm or less in
diameter, without tumor invasion of blood vessels or
lymph nodes) [5]. In subsequent studies, it was shown that
the selection criteria should not be as restrictive as the
Milan criteria, and a number of extended criteria have
been proposed, such as the University of California San
Francisco (UCSF) criteria by Yao et al. in 2001 [6], the
Hangzhou criteria (total tumor diameter ≤ 8 cm; or total
tumor diameter > 8 cm, with histopathologic grade I or II
and pre-operative AFP level ≤ 400 ng/mL, simultaneously)
by Zheng et al. in 2008 [7], and the up-to-seven criteria by
Mazzaferro et al. in 2009 [8], respectively. After expansion,
increased numbers of eligible HCC patients were provided
the chance to be transplanted, with an increase of 16.3%
by the UCSF criteria and up to 51.5% by the Hangzhou
criteria in the Chinese population [9]. Although there is
no statistically significant difference in post-transplant sur-
vival between the expanded criteria and the Milan criteria,
a mathematic decrease in survival rates was shown in
patients exceeding the Milan but fulfilling the expanded
criteria compared with those fulfilling the Milan criteria
[6, 7, 9]. This situation indicates that there are always
exceptional patients exceeding the Milan but fulfilling
the expanded criteria who will not benefit from LT, so
it is important to differentiate these high-risk tumor
recurrence patients from the waiting list.
Recently, systemic inflammation has been shown to
be related to a poor prognosis and increased tumor
progression. As a marker of the systemic inflammatory
response, the platelet-to-lymphocyte ratio (PLR) has
been shown to be a prognostic factor for various tu-
mors [10, 11]. Our previous study also identified that
an elevated PLR predicted increased HCC recurrence
rates after LT [12]. In this study, we aimed to investi-
gate the value of PLR in differentiating those high-risk
tumor recurrence candidates who exceed the Milan
but fulfill the Hangzhou criteria and further establish a
new method combining the Hangzhou criteria and




A total of 343 patients who received LT for HCC were
enrolled in this retrospective study, and all the HCC
developed on the background of liver cirrhosis, which
was confirmed by pathology of the explanted liver. The
exclusion criteria were (1) recipient age less than
18 years, (2) patients who died during the first month
after LT, (3) recipients without clinical data and follow-
up data, and (4) patients with pre-transplant sepsis,
hypersplenism, or massive gastrointestinal tract bleeding.
All the LT were performed at the first affiliated hospital,
School of Medicine, Zhejiang University, between January
2003 and December 2013.
Ethical approval was obtained from the Committee of
Ethics in Biomedical Research of Zhejiang University
and conformed to the ethical guidelines of the Declaration
of Helsinki. Written informed consent was obtained from
all participants.
Study design and data collection
The complete blood count was performed every week or
as necessary before LT; the PLR was calculated as the
ratio of the platelet count to the lymphocyte count ac-
cording to the complete blood count performed within
one month before LT; if more than one set of measure-
ments were available for a given patient, only the lowest
PLR value was used.
The diagnosis of HCC and tumor-related characteris-
tics including tumor number, tumor size, macrovascular
invasion, microvascular invasion, and tumor cell differen-
tiation grading were evaluated based on the pathological
findings. The judgment regarding fulfillment of the Milan
or the Hangzhou criteria was based on a pathological
examination of explanted livers.
The recipients’ clinical data including age, gender,
model of end-stage liver disease (MELD) score, hepatitis
B virus (HBV) infection status, and transplantation type
(living donor liver transplantation [LDLT] or deceased
donor liver transplantation [DDLT]) were collected. Pre-
transplant treatment for HCC was also recorded, i.e. sur-
gical resection and interventional therapies including
transarterial chemoembolization, thermal ablation, and
percutaneous ethanol injection.
Follow-up
All transplanted recipients were followed up. Screening
for tumor recurrence was performed by α-fetoprotein
(AFP) measurement and ultrasonography every month
during the first six months and performed every two
months during the second six months. In subsequent
years, the patients received examinations every three to
six months or when necessary. Thoracoabdominal com-
puted tomography was performed every six months or
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when necessary. Bone scan or positron emission tomog-
raphy was carried out in cases of suspected HCC recur-
rence. The date of tumor recurrence was defined as the
time at which the tumor recurrence was confirmed by
radiological examination or AFP measurement. The
recurrence-free survival (RFS) of patients was recorded.
Statistical analysis
Data are summarized as the mean with standard deviation
(SD) for continuous variables and percentages for discrete
variables. Student’s t test and the Mann–Whitney U test
were used for the comparison of continuous variables with
a normal distribution and non-normal distribution,
respectively. The chi-squared test was used for categorical
variables. Survival analysis was performed using the
Kaplan-Meier method and compared using the log-rank
test. Receiver operating characteristic (ROC) analysis was
used to determine the PLR cut-off value with the most sig-
nificance in terms of predicting tumor recurrence after
LT; the optimal PLR cut-off value was considered when
the highest Youden index (sensitivity + specificity - 1) was
presented. Cox proportional hazards regression was used
to evaluate the risk factors of survival rates. Data were
analyzed using SPSS 16.0 (SPSS Inc. Chicago, CA, USA).
A P value <0.05 was considered statistically significant.
Results
Clinical characteristics of 343 patients received LT for HCC
A total of 500 LT for HCC were performed, and 343
HCC patients were enrolled in this study after exclusion
(Fig. 1). The mean age of recipients was 49.4 (19.0–71.0)
years, and 308 (89.8%) cases were males and 35 (10.2%)
were females. Of these patients, 320 (93.3%) were HBV
infected, the pre-transplant MELD score was 13.0 ± 6.0,
and LDLT was performed in 41 (12.0%) patients. Before
LT, 52 (15.2%) patients received surgical tumor resec-
tions and 170 (49.6%) received interventional therapies.
The mean follow-up period was 57.7 months, ranging
from 33.5–156.0 months.
Outcomes of patients divided according to the Milan and
Hangzhou criteria
Of these patients, 144 (42.0%) patients were within the
Milan criteria (in-Milan group), 49 (14.3%) were beyond
the Milan but within the Hangzhou criteria (Milan ~
Hangzhou group), and the remaining 150 patients (43.7%)
were beyond the Hangzhou criteria (out-Hangzhou
group). The 1-, 3-, and 5-year RFS of patients in the
out-Hangzhou group were 32.3%, 17.6%, and 15.1%, re-
spectively, significantly worse than the other two groups.
The 1-, 3-, and 5-year RFS of the Milan ~Hangzhou
group were 76.1%, 62.6%, and 62.6%, respectively, less
than the 85.1%, 73.4%, and 72.2% of the in-Milan group,
respectively, but no statistically significant difference was
presented (Fig. 2).
Stratification of patients in the Milan ~ Hangzhou group
by pre-transplant PLR values
The stratification analysis of patients in the Milan ~
Hangzhou group was performed using different PLR
values. As described previously [12], we used the ROC
Fig. 1 Schematic diagram of valid patients selection. A total of 500
cases of LT for HCC were performed, of these cases, 157 cases were
excluded by exclusion criteria and 343 HCC patients were enrolled
in this study
Fig. 2 Outcomes of patients divided according to the Milan and
Hangzhou criteria. The patients were divided into in-Milan group,
Milan ~ Hangzhou group, and out-Hangzhou group. The 1-, 3-, and
5-year RFS of patients in the out-Hangzhou group were significantly
worse than the other two groups. The RFS of the Milan ~ Hangzhou
group were less than that of the in-Milan group, but no statistically
significant difference was presented
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curve to determine the PLR cut-off value with the most
significance in predicting tumor recurrence after LT; the
Youden index was highest when the PLR was 120 with a
sensitivity and specificity of 61.6% and 62.7%, respectively.
Therefore, we considered PLR = 120 as the optimal cut-
off. After stratification, the 49 patients in the Milan ~
Hangzhou group were divided into the Milan ~Hangzhou
and PLR < 120 group (40 patients) and the Milan ~
Hangzhou and PLR ≥ 120 group (9 patients).
Comparison of survival rates after stratification by PLR
As shown in Fig. 3, there were significant differences
between the RFS of the two sub-groups divided according
to PLR 120 (P = 0.000). The 1-, 3-, and 5-year RFS of the
Milan ~Hangzhou and PLR < 120 group were 84.2%,
73.3%, and 73.3%, respectively, comparable with 85.7%,
73.9%, and 72.8%, respectively, of the in-Milan group
(P = 0.885). To our surprise, the Milan ~ Hangzhou and
PLR ≥ 120 group showed very poor outcomes which were
similar to those of the out-Hangzhou group, i.e. the 1-, 3-,
and 5-year RFS were 37.5%, 12.5%, and 12.5% vs. 32.3%,
17.6%, and 15.1%, respectively (P = 0.887).
We further stratified the patients fulfilling the Milan
criteria or exceeding the Hangzhou criteria using PLR
120, but we could not find significant differences in
RFS in either the in-Milan (Fig. 4a) or out-Hangzhou
group (Fig. 4b). In addition, we also used different PLR
cut-off values (90, 100, 110, 130, and 140) to do the
survival analysis, but we failed to find any differentiate
value of PLR in HCC patients fulfilling the Milan cri-
teria (Additional file 1: Figure S1), or exceeding the
Hangzhou criteria (Additional file 2: Figure S2).
Establishment of the Hangzhou criteria & PLR method
Based on our present study, we developed the so-called
“Hangzhou criteria & PLR method”: patients exceeding
the Milan but fulfilling the Hangzhou criteria with PLR
< 120, together with those fulfilling the Milan criteria,
were regarded as fulfilling the Hangzhou criteria &
PLR method, while patients exceeding the Milan but
fulfilling the Hangzhou criteria with PLR ≥ 120 as well
as patients exceeding the Hangzhou criteria should be
regarded as exceeding the Hangzhou criteria & PLR
method.
Using the Hangzhou criteria & PLR method, the
ROC analysis showed that the ROC area was 0.768 for
RFS, higher than that of the current selection criteria
including the Milan, UCSF, up-to-seven, and Hangzhou
criteria (Fig. 5a).
In our cohort, compared to the Milan criteria, the
UCSF, up-to-seven, Hangzhou criteria provided an
expansion of 15.3% (n = 22), 17.4% (n = 25), and 34.0%
(n = 49), respectively. The expansion of Hangzhou cri-
teria & PLR method was 27.8% (n = 40), lower than that
of Hangzhou criteria, but higher than that of UCSF and
up-to-seven criteria (Fig. 5b).
Tumor-related characteristics and clinical data in the
Milan ~ Hangzhou and PLR < 120 and Milan ~ Hangzhou
and PLR ≥ 120 groups
In order to identify an explanation for the poor out-
comes in the Milan ~ Hangzhou and PLR ≥ 120 group,
we evaluated the distribution of tumor-related charac-
teristics and clinical data between the PLR ≥ 120 and
< 120 groups of patients exceeding the Milan but fulfilling
the Hangzhou criteria. As shown in Table 1, we found that
a high proportion of patients with PLR ≥ 120 had a large
tumor size of ≥ 7 cm, pre-transplant partial hepatectomy
and interventional therapies. There was no difference in
terms of recipient age, gender, MELD score, AFP level,
HBV infection status, LDLT, microvascular invasion,
tumor lesion number, or tumor differentiation. This result
indicates that patients with PLR ≥ 120 tended to be as-
sociated with a large tumor size, pre-transplant partial
hepatectomy and interventional therapies. These dis-
parities may be an explanation for the poor prognosis
of patients with PLR ≥ 120.
Fig. 3 Comparison of survival rates after stratification by PLR. After
stratification, the patients were divided into in-Milan group, Milan ~
Hangzhou & PLR < 120 group, Milan ~ Hangzhou & PLR≥ 120 group,
and out-Hangzhou group. The 1-, 3-, and 5-year RFS of the Milan ~
Hangzhou & PLR < 120 group were comparable with that of the
in-Milan group. The Milan ~ Hangzhou & PLR≥ 120 group showed
poor outcomes which were similar to those of the out-Hangzhou group
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Univariate and multivariate analysis of risk factors for RFS
of patients in Milan ~ Hangzhou group
The univariate Cox regression analysis showed that pre-
transplant PLR ≥ 120, AFP ≥ 200 ng/ml and pre-LT surgi-
cal resection were risk factors of RFS of patients in
Milan ~Hangzhou group. Based on multivariate Cox re-
gression analysis, pre-transplant PLR ≥ 120 (hazard ratio
[HR] = 5.194, P = 0.020) and AFP ≥ 200 ng/ml (HR = 4.313,
P = 0.004) were confirmed as independent risk factors of
RFS of HCC patients in Milan ~Hangzhou group
(Table 2).
Discussion
Since the induction of the Milan criteria by Mazzaferro
et al. in 1996, excellent clinical outcomes after LT have
been achieved for HCC patients fulfilling the Milan cri-
teria [5, 13]. In the following decades, the selection criteria
were expanded effectively and safely [6, 7]. The current
selection criteria are based solely or mainly on a pre-
transplant radiological examination, which places no
consideration on tumor biological behavior and is limited
in detecting small tumor lesions. Radiological imaging has
been reported to be insufficiently accurate and always
underestimates the real tumor status [14]. To avoid the
bias caused by radiological imaging, many studies have
been performed to identify biological markers which can
be used in combination with the current selection criteria,
including AFP [15], matrix metalloproteinase-9 [16],
osteopontin [17], and albumin mRNA [18]. For example,
Sieghart et al. indicated that serum osteopontin is an inde-
pendent predictor of RFS in patients beyond the Milan
criteria, and the authors suggested that osteopontin
staining in liver biopsies should be performed at the
time of LT, especially for the candidates exceeding the
Milan criteria [17]. Recently, Xu et al. studied a large
cohort of Chinese HCC patients and stratified patients
fulfilling the Hangzhou criteria into type A (tumor burden
≤8 cm or tumor burden >8 cm, but with AFP ≤100 ng/mL
Fig. 4 Differentiate value of PLR for patients of in-Milan or out-Hangzhou group. The patients of in-Milan or out-Hangzhou group were divided
by PLR 120, there was no significant difference in RFS in either the in-Milan (Panel a) or out-Hangzhou group (Panel b)
Fig. 5 The comparison of different selection criteria. The ROC analysis
showed that the ROC area of Hangzhou criteria & PLR method was
higher than that of the current selection criteria including the Milan,
UCSF, up-to-seven, and Hangzhou criteria (Panel a). The expansion of
Hangzhou criteria & PLR method was lower than that of Hangzhou
criteria, but higher than that of UCSF and up-to-seven criteria (Panel b)
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and well to moderate differentiation) and type B (tumor
burden >8 cm, but AFP between 100 and 400 ng/mL and
well to moderate differentiation). These authors found
that Hangzhou type B was associated with a relatively
poor prognosis, and suggested that Hangzhou type B
should be regarded as a relative contraindication for LT
considering the shortage of organs [9].
In our study, the pre-transplant PLR was employed in
combination with Hangzhou criteria to select HCC can-
didates for LT. In recent years, studies have confirmed
that elevated systemic inflammation predicts poor prog-
nosis in various kinds of cancers, including HCC [19].
The tumor can stimulate the inflammatory process, and
inflammatory cells can promote angiogenesis, tumor
proliferation, and metastasis by complicated molecular
mechanisms [20, 21]. Various indices have been used to
evaluate systemic inflammation, including the PLR,
neutrophil-to-lymphocyte ratio [22], and modified Glas-
gow prognostic score [23]. All these indices can be easily
calculated based on routinely performed blood tests in
the clinical work-up. For PLR, it can be used to predict
the prognosis of HCC patients receiving transarterial
chemoembolization [24], thermal ablation [25], or partial
hepatectomy [26]. Our previous work also confirmed
that pre-transplant elevated PLR was associated with a
high proportion of multiple tumors, large tumor size,
micro- and macrovascular invasion, and predicted post-
transplant tumor recurrence [12].
Our present study identified that HCC patients
exceeding the Milan but fulfilling the Hangzhou criteria
could be stratified effectively by the pre-transplant PLR
value. After stratification, the patients exceeding the
Milan but fulfilling the Hangzhou criteria with PLR ≥
120 showed poor outcomes, which were very similar to
those of patients exceeding the Hangzhou criteria, indi-
cating that PLR ≥ 120 effectively excludes high-risk
tumor recurrence patients from candidates exceeding
the Milan but fulfilling the Hangzhou criteria. The prog-
nosis of patients exceeding the Milan but fulfilling the
Hangzhou criteria with PLR < 120 was almost the same
as patients fulfilling the Milan criteria. Furthermore, the
multivariate analysis confirmed that PLR ≥ 120 was an
independent risk factor of RFS of HCC patients exceed-
ing the Milan but fulfilling the Hangzhou criteria. Con-
sistent with previous studies [27], PLR failed to predict
post-transplant tumor recurrence for patients fulfilling
the Milan criteria. Our results show that patients fulfill-
ing the Milan criteria can obtain satisfactory outcomes
whether elevated pre-transplant PLR is present or not.
In line with our estimation, patients exceeding the
Hangzhou criteria were associated with poor prognosis
regardless of their PLR status.
According to this study, we propose the Hangzhou cri-
teria & PLR method. In this method, patients exceeding
Table 1 Comparison of tumor-related characteristics and clinical
data between the Milan ~ Hangzhou and PLR < 120 and Milan
~ Hangzhou and PLR ≥ 120 groups
Variables Milan ~ Hangzhou group P value
PLR < 120 (n = 40) PLR ≥ 120 (n = 9)
Age (years) 50.5 ± 8.4 51.3 ± 11.2 0.802
Gender (Male) 36 (90.0%) 7 (77.8%) 0.302
MELD score 12.6 ± 4.6 10.4 ± 2.5 0.062
AFP (ng/ml) 675.1 ± 1282.9 1248.0 ± 2808.1 0.565
HBV infection 37 (92.5%) 7 (77.8%) 0.224
Blood cell count (*109/L)
Neutrophil 2.1 ± 1.4 2.4 ± 2.3 0.740
Lymphocyte 1.1 ± 0.7 0.7 ± 0.4 0.089
Platelet 84.0 ± 64.4 153.2 ± 108.5 0.098
Pre-LT treatment
Surgical resection 5 (12.5%) 4 (44.4%) 0.046
Interventional therapy 18 (45.0%) 8 (88.9%) 0.026
Types of LT 1.000
LDLT 3 (7.5%) 0 (0.0%)
DDLT 37 (92.5%) 9 (100.0%)
Solitary tumor 19 (47.5%) 6 (66.7%) 0.463
Maximal tumor ≥ 7 cm 7 (17.5%) 5 (55.6%) 0.029
Well-moderate
differentiation
28 (70.0%) 8 (88.9%) 0.412
Microvascular invasion 8 (20.0%) 1 (11.1%) 1.000
Table 2 Univariate and multivariate analysis of risk factors for
RFS of patients in Milan ~ Hangzhou group
Characteristics Univariate Multivariate
P P HR (95% CI)
Recipient
Age≥ 60 years 0.093
Gender (Male) 0.067
MELD score≥ 20 0.517
HBV infection 0.852
Types of LT: LDLT 0.219
PLR≥ 120 0.000 0.020 5.194 (1.293 ~ 20.865)
Tumor-related
Pre-LT treatment
Surgical resection 0.023 0.919 1.082 (0.236 ~ 4.966)
Interventional therapy 0.539
AFP≥ 200 ng/ml 0.000 0.004 4.313 (1.591 ~ 11.695)
Solitary tumor 0.118





Xia et al. BMC Cancer  (2017) 17:14 Page 6 of 8
the Milan but fulfilling the Hangzhou criteria with PLR
< 120 should be regarded homogenously as those fulfilling
the Milan criteria; similarly, patients exceeding the
Hangzhou criteria, and patients who exceed the Milan but
fulfill the Hangzhou criteria with PLR ≥ 120 should be
regarded as contraindicated for LT. The ROC analysis
confirmed the feasibility of this new method and demon-
strated its superiority to other selection criteria. Com-
pared to the Milan criteria, 40 (27.8%) more patients were
provided the option of LT by the Hangzhou criteria &
PLR method without any sacrifice in prognosis.
One limitation of our study was the small number of
enrolled patients, and all these recipients were Chinese
citizens and majority of them were hepatitis B virus
infected. Further studies based on a larger, multi-center
cohort need to be carried out to verify our conclusions.
The advantage of our study was that the PLR value we
used can be obtained easily and conveniently from the
routinely performed complete blood count, in contrast
to other molecular or genetic markers or complicated
mathematical predictive models.
Conclusions
In order to maximize recipient benefit and make full use
of scarce liver grafts, we suggest that pre-transplant PLR
can be combined with the Hangzhou criteria to select
LT candidates more carefully. The Hangzhou criteria
combined with the pre-transplant PLR can accurately
exclude high-risk tumor recurrence recipients; this
approach expands the Milan criteria effectively without
any sacrifice.
Additional files
Additional file 1: Figure S1. RFS of patients fulfilling the Milan criteria
stratified by different pre-transplant PLR values. For patients who fulfilled
the Milan criteria, the RFS was comparable after stratification by different
PLR cut-off values (90, 100, 110, 130, and 140). (TIF 738 kb)
Additional file 2: Figure S2. Differentiate value of PLR for patients
exceeding the Hangzhou criteria. There was no significant difference in
RFS for patients exceeding the Hangzhou criteria after stratification by
different PLR cut-off values (90, 100, 110, 130, and 140). (TIF 52 kb)
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